ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu
RANCHO CORDOVA, Calif., July 17, 2023 /PRNewswire/ — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced the appointments of Biao Xi, Ph.D. and James Xu, Esq., DBA, PsyD., J.D., CPA to its Board, effective July 17, 2023. Both are independent directors. The appointments expand ThermoGenesis’ Board to seven members.
Related news for (THMO)
- ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update
- ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento
- ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference